Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

26.7%

16 terminated/withdrawn out of 60 trials

Success Rate

62.8%

-23.8% vs industry average

Late-Stage Pipeline

3%

2 trials in Phase 3/4

Results Transparency

0%

0 of 27 completed trials have results

Key Signals

8 recruiting13 terminated

Enrollment Performance

Analytics

N/A
31(58.5%)
Phase 2
16(30.2%)
Phase 1
2(3.8%)
Early Phase 1
2(3.8%)
Phase 3
1(1.9%)
Phase 4
1(1.9%)
53Total
N/A(31)
Phase 2(16)
Phase 1(2)
Early Phase 1(2)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (60)

Showing 20 of 60 trials
NCT07178847Not ApplicableRecruiting

cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas

Role: lead

NCT07624994Phase 2Not Yet Recruiting

Functional Imaging of Digital Osteoarthritis and Rheumatoid Arthritis Using 99mTc-NTP 15-5 in Nuclear Medicine

Role: lead

NCT05710679Not ApplicableRecruiting

Prediction of Residual Disease by Circulating DNA Detection After Potentiated Radiotherapy for Locally Advanced Head and Neck Cancer

Role: lead

NCT04068623Active Not Recruiting

Correlation Between TILs and Blood Cell Counts in Triple Negative Breast Cancer Patients

Role: lead

NCT03068663Not ApplicableActive Not Recruiting

Microbiota and the Lung Cancer

Role: lead

NCT04133077Not ApplicableRecruiting

Xenografts Development From Surgical Tumor Samples of Patients With Triple Negative or Luminal B Breast Cancer

Role: lead

NCT06550674Not ApplicableRecruiting

Identification of New Candidate Genes for Hereditary Predisposition to Uveal Melanoma

Role: lead

NCT03020251Not ApplicableCompleted

Effects of Preoperative Rehabilitation in Patients Resected for Lung Cancer

Role: lead

NCT07361471Not ApplicableRecruiting

Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy

Role: lead

NCT06512558Not ApplicableRecruiting

Augmented Reality Feasibility for Non-invasive Preoperative Tracking in Breast Cancer Surgery

Role: lead

NCT06600802Not ApplicableRecruiting

Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer

Role: lead

NCT04438681Active Not Recruiting

Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients

Role: lead

NCT04503772Phase 2Completed

Preoperative Stereotactic Radiosurgery for Brain Metastases

Role: lead

NCT05157594Completed

hPG80 (Circulating Progastrin) as a Blood Biomarker for High-grade Glial Tumors

Role: lead

NCT04273542Not ApplicableActive Not Recruiting

Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer Screening

Role: lead

NCT05433077Active Not Recruiting

Support and Post-therapeutic Rehabilitation for Women in Complete Remission of Breast Cancer in a Thermal Environment

Role: lead

NCT06062199Not ApplicableRecruiting

Impact of Implementing the Modified A-DIVA Scale on Successful Access to a Venous Line on the First Attempt

Role: lead

NCT04881032Phase 1Active Not Recruiting

AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma

Role: lead

NCT03784625Early Phase 1Completed

Targeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF01012

Role: lead

NCT03401840Not ApplicableCompleted

STEREO-POSTOP 01 (PostOperative Hypofractionated Stereotactic Body Radiotherapy ) - GORTEC 2017-03

Role: lead